1ACTA|CAS 2196076-49-8|DC Chemicals

Cas No.:	2196076-49-8
Chemical Name:	1ACTA
SMILES:	CC(NC1=CC=CC2=C1CCCN2C(C=C)=O)=O
Formula:	C₁₄H₁₆N₂O₂
M.Wt:	244.29
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC77014	IXA62	IXA62 is an orally active and selective IRE1/XBP1s activator (EC50 = 0.31 μM) that reduces Aβ secretion. IXA62 enhances glucose-stimulated insulin secretion from rat insulinoma cells.
DC77013	1ACTA	1ACTA is an IRE1α S-Nitrosylation inhibtor, maintaining the endoplasmic reticulum stress response under nitrosative stress.
DC73839	TC-D-F07	TC-D-F07 is a novel prodrug of the covalent IRE-1 inhibitor D-F07, inhibits IRE-1/XBP-1s pathway in cancer cells.
DC73838	PAIR1	PAIR1 is a partial antagonist of IRE1α RNase (PAIR) that fully engage IRE1α's kinase domain (Ki=220 nM) but only partially inhibit its RNase activity.
DC73837	D-F07	D-F07 is a novel fluorescent, covalent IRE-1 inhibitor, potently inhibits XBP-1s expression in MM cells.
DC71403	PAIR2	PAIR2 is a potent and selective partial antagonist of IRE1α RNase. PAIR2 can completely occupy IRE1α’s ATP-binding site in cells and block the ability of a potent KIRA to inhibit XBP1 splicing.
DC71145	KIRA9	KIRA9 is a potent IRE1 inhibitor (IC50=4.8 μM in INS-1 cells). KIRA9 is able to fully engage the ATP-binding site of IRE1α. KIRA9 can block ER-localized mRNA decay and apoptosis.
DC70125	GSK2850163	A novel potent IRE1α-selective kinase inhibitor that inhibits both the kinase and RNase activities of IRE1α with IC50 of 20 nM and 200 nM, respectively; binds to pIRE1α and inhibits XBP 1 splicing; only weakly inhibits Ron (IC50= 4.4 uM) and FGFR1 V561M (IC50=17 uM) in a panel of 284 kinases.
DC48263	IRE1α kinase-IN-6	IRE1α kinase-IN-6 is a potent IRE1α inhibitor with an IC50 value of 4.4 nM.